Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Abstract

Background: Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. FOLFOX is the most common regimen used in the first-line chemotherapy in advanced colorectal cancer, but only half of the patients respond to this regimen and we have almost no clue in predicting resistance in such first-line application. Methods: To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative realtime PCR. Results: 62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis. Among them, 5 (miR-221, miR-222, miR-122, miR-19a, miR-144) were chosen for further validation in an independent population (N=72). Our results indicated serum miR-19a to be significantly up-regulated in resistance-phase serum (p=0.009). The ROC curve analysis showed that the sensitivity of serum miR-19a to discriminate the resistant patients from the response ones was 66.7%, and the specificity was 63.9% when the AUC was 0.679. We additionally observed serum miR-19a had a complementary value for cancer embryonic antigen (CEA). Stratified analysis further revealed that serum miR-19a predicted both intrinsic and acquired drug resistance. Conclusions: Our findings confirmed aberrant expression of serum miR-19a in FOLFOX chemotherapy resistance patients, suggesting serum miR-19a could be a potential molecular biomarker for predicting and monitoring resistance to first-line FOLFOX chemotherapy regimens in advanced colorectal cancer patients.

Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer

“…Among them, finding biomarkers for prognosis has long been a hotspot (Huang et al, 2012;Qian et al, 2012;Zhang et al, 2012;Chen et al, 2013;Cui et al, 2013;Dong et al, 2013;Sisik et al, 2013;Wu et al, 2013). Myosins have a well-characterized biological function in using the energy of ATP hydrolysis to move actin filaments to produce muscle force.…”

Structural Maintenance of Chromosomes 4 is a Predictor of Survival and a Novel Therapeutic Target in Colorectal Cancer

“…Despite several genes have being proved that relate to genesis of CRC, the exact mechanisms underlying he development and progression CRC are still poorly understood (Goel and Boland, 2010). Throughout the articles relate to CRC in the journal ACJCP over the past two years, it is not difficult to find that the novel molecular markers with potential of treatment and prognosis have captured more and more attention (Chen et al, 2013;Zhu et al, 2013). Given this consideration, it is imperative to seek out a key gene associated with the progression and pathogenesis.…”

MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

“…The study demonstrated that pre-therapy plasma miRNAs may serve as non-invasive markers to predict outcome in mCRC patients treated with 5-FU/oxaliplatin chemotherapy [89]. Aberrant elevation of serum miR-19a was also found to predict non-responders to FOLFOX chemotherapy in advanced CRC [90]. Another study identified a distinct serum miRNA expression signature in response to chemotherapy.…”